Research programme: neuromuscular disorder therapeutics - Neurotune

Drug Profile

Research programme: neuromuscular disorder therapeutics - Neurotune

Alternative Names: NT-1654

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurotune
  • Class Biological factors; Small molecules
  • Mechanism of Action Acetylcholine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Congenital myasthenic syndromes; Myasthenia gravis; Peripheral nerve injuries; Spinal muscular atrophy
  • No development reported Amyotrophic lateral sclerosis; Muscular atrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Switzerland (SC)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Muscle-wasting in Switzerland (SC)
  • 01 Oct 2015 Preclinical trials in Congenital myasthenic syndromes in Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top